101 related articles for article (PubMed ID: 8847967)
1. Behavioral effects of (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, (DOI) in the elevated plus-maze test.
Onaivi ES; Bishop-Robinson C; Darmani NA; Sanders-Bush E
Life Sci; 1995 Nov; 57(26):2455-66. PubMed ID: 8847967
[TBL] [Abstract][Full Text] [Related]
2. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice.
Halberstadt AL; van der Heijden I; Ruderman MA; Risbrough VB; Gingrich JA; Geyer MA; Powell SB
Neuropsychopharmacology; 2009 Jul; 34(8):1958-67. PubMed ID: 19322172
[TBL] [Abstract][Full Text] [Related]
3. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD).
Schindler EA; Dave KD; Smolock EM; Aloyo VJ; Harvey JA
Pharmacol Biochem Behav; 2012 Mar; 101(1):69-76. PubMed ID: 22197710
[TBL] [Abstract][Full Text] [Related]
4. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen.
Canal CE; Olaghere da Silva UB; Gresch PJ; Watt EE; Sanders-Bush E; Airey DC
Psychopharmacology (Berl); 2010 Apr; 209(2):163-74. PubMed ID: 20165943
[TBL] [Abstract][Full Text] [Related]
5. Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex.
Schindler EA; Harvey JA; Aloyo VJ
Brain Res; 2013 Jan; 1491():98-108. PubMed ID: 23123701
[TBL] [Abstract][Full Text] [Related]
6. Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT2A receptors.
Chaouloff F; Kulikov A; Mormède P
Eur J Pharmacol; 1997 Sep; 334(1):25-9. PubMed ID: 9346323
[TBL] [Abstract][Full Text] [Related]
7. Regulation of 5-HT(2A) receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin.
Anji A; Kumari M; Sullivan Hanley NR; Bryan GL; Hensler JG
Neuropharmacology; 2000 Aug; 39(11):1996-2005. PubMed ID: 10963743
[TBL] [Abstract][Full Text] [Related]
8. Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (+/- )-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin.
Darmani NA; Martin BR; Glennon RA
J Pharmacol Exp Ther; 1992 Aug; 262(2):692-8. PubMed ID: 1501117
[TBL] [Abstract][Full Text] [Related]
9. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
Marek GJ; Aghajanian GK
J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
[TBL] [Abstract][Full Text] [Related]
10. Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors.
Krebs-Thomson K; Paulus MP; Geyer MA
Neuropsychopharmacology; 1998 May; 18(5):339-51. PubMed ID: 9536447
[TBL] [Abstract][Full Text] [Related]
11. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ
J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755
[TBL] [Abstract][Full Text] [Related]
12. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice.
Berendsen HH; Broekkamp CL
Br J Pharmacol; 1990 Nov; 101(3):667-73. PubMed ID: 2150180
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of ear-scratch response in mice as a behavioral model for selective 5-HT2-receptor agonists and evidence for 5-HT1B- and 5-HT2-receptor interactions.
Darmani NA; Martin BR; Pandey U; Glennon RA
Pharmacol Biochem Behav; 1990 Sep; 37(1):95-9. PubMed ID: 2263671
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
Kleven MS; Assié MB; Koek W
J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
[TBL] [Abstract][Full Text] [Related]
15. The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats.
Scruggs JL; Schmidt D; Deutch AY
Neurosci Lett; 2003 Aug; 346(3):137-40. PubMed ID: 12853103
[TBL] [Abstract][Full Text] [Related]
16. Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin.
Krebs-Thomson K; Lehmann-Masten V; Naiem S; Paulus MP; Geyer MA
Eur J Pharmacol; 1998 Feb; 343(2-3):135-43. PubMed ID: 9570460
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone.
Schreiber R; Brocco M; Millan MJ
Eur J Pharmacol; 1994 Oct; 264(1):99-102. PubMed ID: 7530204
[TBL] [Abstract][Full Text] [Related]
18. 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI) exerts an anorexic action that is blocked by 5-HT2 antagonists in rats.
Schechter LE; Simansky KJ
Psychopharmacology (Berl); 1988; 94(3):342-6. PubMed ID: 3128809
[TBL] [Abstract][Full Text] [Related]
19. Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane.
Garcia EE; Smith RL; Sanders-Bush E
Neuropharmacology; 2007 Jun; 52(8):1671-7. PubMed ID: 17493641
[TBL] [Abstract][Full Text] [Related]
20. Differential ontogenesis of three DOI-induced behaviors in mice.
Darmani NA; Shaddy J; Gerdes CF
Physiol Behav; 1996 Dec; 60(6):1495-500. PubMed ID: 8946497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
